New opportunities of therapy of severe atopic dermatitis

Cover Page

Cite item

Full Text

Abstract

This article presents a case of the successful use of dupilumab in a 21-year-old patient with severe atopic dermatitis, concomitant bronchial asthma, and allergic rhinitis. The patient was observed in the allergological department of the Krasnoyarsk Clinical Regional Hospital for 2 years. The disease was characterized by constant skin symptoms, frequent exacerbations, resistance to standard therapy, including systemic glucocorticosteroids and immunosuppressors. Considering the above factors, targeted therapy was started with dupilumab, registered in the Russian Federation for use in atopic dermatitis resistant to standard therapy. Against the background of biological therapy (13 injections were carried out), a stable significant decrease in skin syndrome activity was achieved (SCORAD index decreased from 72 to 9 points), and the patient’s quality of life significantly improved.

About the authors

Irina v Demko

Professor V.F. Voino-Yasenetsky Krasnoyarsk State Medical University; Krasnoyarsk Clinical Regional Hospital

Email: demko64@mail.ru
ORCID iD: 0000-0001-8982-5292
SPIN-code: 6520-3233

MD, Dr. Sci. (Med.), Professor

Russian Federation, 1, Partizan Zheleznyak str., Krasnoyarsk, 660022; Krasnoyarsk

Elena A. Sobko

Professor V.F. Voino-Yasenetsky Krasnoyarsk State Medical University; Krasnoyarsk Clinical Regional Hospital

Email: sobko29@mail.ru
ORCID iD: 0000-0002-9377-5213
SPIN-code: 9132-6756

MD, Dr. Sci. (Med.), Professor

Russian Federation, 1, Partizan Zheleznyak str., Krasnoyarsk, 660022; Krasnoyarsk

Angelina Yu. Kraposhina

Professor V.F. Voino-Yasenetsky Krasnoyarsk State Medical University; Krasnoyarsk Clinical Regional Hospital

Author for correspondence.
Email: angelina-maria@inbox.ru
ORCID iD: 0000-0001-6896-877X
SPIN-code: 8829-9240

MD, Cand. Sci. (Med.), Associate Professor

Russian Federation, 1, Partizan Zheleznyak str., Krasnoyarsk, 660022; Krasnoyarsk

Natalia A. Shestakova

Professor V.F. Voino-Yasenetsky Krasnoyarsk State Medical University; Krasnoyarsk Clinical Regional Hospital

Email: barsk@rambler.ru
ORCID iD: 0000-0002-2252-7423
SPIN-code: 4579-4502

MD, Cand. Sci. (Med.)

Russian Federation, 1, Partizan Zheleznyak str., Krasnoyarsk, 660022; Krasnoyarsk

Natalia V. Gordeeva

Professor V.F. Voino-Yasenetsky Krasnoyarsk State Medical University; Krasnoyarsk Clinical Regional Hospital

Email: natagorday@yandex.ru
ORCID iD: 0000-0002-0586-8349
SPIN-code: 7914-7630

MD, Cand. Sci. (Med.), Associate Professor

Russian Federation, 1, Partizan Zheleznyak str., Krasnoyarsk, 660022; Krasnoyarsk

Karina F. Kasymova

Professor V.F. Voino-Yasenetsky Krasnoyarsk State Medical University

Email: ayaneshiroi@gmail.com
ORCID iD: 0000-0001-8448-6113
SPIN-code: 4691-2399

MD

Russian Federation, 1, Partizan Zheleznyak str., Krasnoyarsk, 660022

References

  1. Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657–682. doi: 10.1111/jdv.14891
  2. Kozyeva VV. Prevalence of bronchial asthma and atopic dermatitis in children. Allea nauki. 2017;3(9):469–472. (In Russ).
  3. Dyneva ME, Aminova GE, Kurbacheva OM, et al. Dupilumab: new opportunities for the treatment of asthma and chronic rhinosinusitis with nasal polyps. Russian Journal of Allergy. 2021;18(1):18–31. (In Russ). doi: 10.36691/RJA1408
  4. Smolkin YS, Balabolkin II, Gorlanov IA, et al. Consensus document APAIR: atopic dermatitis in children — update 2019 (short version). Part 1. Allergol Immunol Pediatr. 2020;60(1):4–25. doi: 10.24411/2500-1175-2020-10001
  5. Snast I, Reer O, Hodak E, et al. Are biologics efficacious in atopic dermatitis? A systematic review and meta-analysis. Am J Clin Dermatol. 2018;19(2):145–165. doi: 10.1007/s40257-017-0324-7
  6. Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335–2348. doi: 10.1056/NEJMoa1610020
  7. Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287–2303. doi: 10.1016/S0140-6736(17)31191-1
  8. Thaçi D, Simpson E, Deleuran M, et al. Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2). J Dermatol Sci. 2019;94(2):266–275. doi: 10.1016/j.jdermsci.2019.02.002
  9. Lowe AJ, Leung DY, Tang ML, et al. The skin as a target for prevention of the atopic march. Ann Allergy Asthma Immunol. 2018;120(2):145–151. doi: 10.1016/j.anai.2017.11.023
  10. Williams H, Flohr C. How epidemiology has challenged 3 prevailing concepts about atopic dermatitis. J Allergy Clin Immunol. 2006;118(1):209–213. doi: 10.1016/j.jaci.2006.04.043
  11. Smolkin YS, Masalsky SS, Smolkina OY. The application of the biological treatment in atopic dermatitis: focus on dupilumab. Allergology and Immunology in Pediatrics. 2020;61(2):27–40. (In Russ). doi: 10.24411/2500-1175-2020-10005
  12. Zayed Y, Kheiri B, Banifadel M, et al. Dupilumab safety and efficacy in uncontrolled asthma: a systematic review and meta-analysis of randomized clinical trials. J Asthma. 2019;56(10):1110–1119. doi: 10.1080/02770903.2018.1520865
  13. Tozawa H, Kanki Y, Suehiro J, et al. Genome-wide approaches reveal functional interleukin-4-inducible STAT6 binding to the vascular cell adhesion molecule 1 promoter. Mol Cell Biol 2011;31(11):2196–2209. doi: 10.1128/MCB.01430-10
  14. Mineev VN, Sorokina LN, Trofimov VI, et al. Interleukin-4 and interleukin-13 receptors: structure, function and genetic polymorphism. Pulmonology. 2010;(3):113–119. (In Russ).
  15. Fleming P, Drucker AM. Risk of infection in patients with atopic dermatitis treated with dupilumab: a meta-analysis of randomized controlled trials. J Am Acad Dermatol. 2018;78(1):62–69. doi: 10.1016/j.jaad.2017.09.052
  16. Balabolkin II, Terletskaya RN, Modestov AA. Allergic morbidity of children in modern environmental conditions. Siberian Medical Review. 2015;91(1):63–67. (In Russ).

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Disease activity (SCORAD) against background of dupilumab use

Download (116KB)
Indexing metadata
3. Fig. 2. Number of eosinophils in peripheral blood against background of dupilumab preparation application

Download (107KB)
Indexing metadata

Copyright (c) 2021 Pharmarus Print Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies